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Abstract
Thrombotic diseases are among the leading causes of morbidity and mortality in the world. To add insights into the genetic
regulation of thrombotic disease, we conducted a genome-wide association study (GWAS) of 6135 self-reported blood clots
events and 252 827 controls of European ancestry belonging to the 23andMe cohort of research participants. Eight loci exceeded
genome-wide signiﬁcance. Among the genome-wide signiﬁcant results, our study replicated previously known venous
thromboembolism (VTE) loci near the F5, FGA-FGG, F11, F2, PROCR and ABO genes, and the more recently discovered locus near
SLC44A2. In addition, our study reports for the ﬁrst time a genome-wide signiﬁcant association between rs114209171, located
upstream of the F8 structural gene, and thrombosis risk. Analyses of expression proﬁles and expression quantitative trait loci
Received and Revised: January 4, 2016. Accepted: February 5, 2016
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com
doi: 10.1093/hmg/ddw037
Advance Access Publication Date: 9 February 2016
1867
Association Studies Article
A S SOC I AT I ON STUD I E S ART I C L E
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/9/1867/2384901 by U
niversity of D
undee user on 14 M
ay 2019
| Human Molecular Genetics, 2016, Vol. 25, No. 9
across different tissues suggested SLC44A2, ILF3 andAP1M2 as the threemost plausible candidate genes for the chromosome 19
locus, our only genome-wide signiﬁcant thrombosis-related locus that does not harbor likely coagulation-related genes.
In addition, we present data showing that this locus also acts as a novel risk factor for stroke and coronary artery disease (CAD).
In conclusion, our study reveals novel common genetic risk factors for VTE, stroke and CAD and provides evidence that self-
reported data on blood clots used in a GWAS yield results that are comparable with those obtained using clinically diagnosed
VTE. This observation opens up the potential for larger meta-analyses, which will enable elucidation of the genetics of
thrombotic diseases, and serves as an example for the genetic study of other diseases.
Introduction
Venous thromboembolism (VTE), which includes deep-vein
thrombosis (DVT) and pulmonary embolism (PE), is a complex dis-
ease determined by well-established environmental and genetic
risk factors. VTE is one of the most common cardiovascular dis-
eases with an incidence of 1.5 per 1000 person-years estimated
in Europe (1–3). Despite the success of genome-wide association
studies (GWAS) in identifying new genetic factors determining
other cardiovascular diseases such as coronary artery disease
(CAD) (4,5), GWAS results for VTE have, until very recently, yielded
little success. One of the reasons for the limited number of loci
identiﬁed forVTE ismost likely lackof power due to the small sam-
ple sizes used so far. In an effort to overcome this, a GWAS meta-
analysis was recently published, which included 7500 cases in the
discovery phase (an almost 4-fold increase over what was previ-
ously published) and reported two novel VTE-associated genes (6).
Despite this notable increase in sample size, a fairly small num-
ber of cases was included compared with the numbers used for
other cardiovascular diseases (for example, 17 900 cases for the
International Stroke Genetics Consortium, or 63 750 cases for the
CardioGramplusC4D Consortium), and in fact, most GWAS meta-
analyses now have sample sizes in the discovery phase exceeding
10 000 individuals (7). As such, concerns about sources of hetero-
geneity and phenotype deﬁnition have been raised, which point
to the need for a balance between sample size and speciﬁc pheno-
type deﬁnition that avoids diluted effect sizes due to phenotype
heterogeneity.While this is true formore complicatedphenotypes,
certain diseases with less complex phenotype deﬁnition could in
theory be analyzed just by use of self-reported information about
disease from questionnaires. The great advantage of this strategy
is that one can take advantage of large cohorts fromwhich genetic
information is available anduse themtoanalyzemultiple different
disease/quantitative/behavioral phenotypes without the need for
highly speciﬁc clinical conﬁrmation, which is often costly and
time-consuming andwhich frequently represents the limiting fac-
tor when gathering sufﬁciently large disease collections. Here we
present, as a proof of concept, the results of a GWAS of VTE
based on web-based self-reported data on thrombotic events
from the 23andMe research participant cohort, which suggest
that strong and reliable association signals can be obtained from
questionnaire-deﬁned phenotypes that contribute to the identiﬁ-
cation and validation of genetic factors affecting this disease. In
addition, we present results from expression proﬁle analyses
across different tissues to elucidate the possible biological me-
chanisms explaining the chromosome 19 locus association with
disease, our only genome-wide signiﬁcant thrombosis-related
locus that does not harbor likely coagulation-related genes, and
we provide evidence for the implications of this novel VTE-asso-
ciated locus on CAD and stroke.
Results
TheManhattan plot for the genome-wide logistic regression ana-
lysis of thrombotic events in 6135 cases and 252 827 controls, of
which 43.1 and 53.4%, respectively, were male, is shown in
Figure 1.
Discovery GWAS
Eight loci exceeded the genome-wide signiﬁcant threshold of
5 × 10−8: the coagulation factor 5 (F5) locus at chromosome
1q24.2 (P = 3.6 × 10−137), the ABO locus at chromosome 9q34.2
(P = 7.1 × 10−63), the coagulation factor 11 (F11) locus at chromo-
some 4q35.2 (P = 7.0 × 10−28), the coagulation factor 2 (F2) locus
at chromosome 11p11.2 (P = 1.3 × 10−24), the ﬁbrinogen cluster
(FGA/FGB/FGG) locus at chromosome 4q31.3 (P = 2.0 × 10−19), the
coagulation factor 8 (F8) locus at chromosome Xq28 (P = 7.0× 10−13),
the recently described locusonchromosome19p13.2 (P= 6.1× 10−9),
which does not contain any coagulation-related candidate gene,
and the protein C receptor (PROCR) locus on chromosome
20q11.22 (P = 6.7 × 10−9). Table 1 shows the lead SNPs in each asso-
ciated region, and themost probable candidate gene (deﬁned as the
nearest gene related to coagulation) in the region. Among these, the
F8 locusassociation is reportedhere for theﬁrst time in aGWAS.Re-
sultswere adjusted for a genomic control inﬂation factor (λ= 1.033).
Regional association plots for the genome-wide signiﬁcant loci are
shown in Supplementary Material, Figure S1.
In addition, four other loci were found with suggestive
evidence of association with thrombosis (5 × 10−8 < P < 10−6): a
locus on chromosome 2p21 (P = 1.9 × 10−7), a locus on chromo-
some 10q22.1 (P = 2.9 × 10−7), a locus on chromosome 6p24.1 (P =
4.4 × 10−7) and a locus on chromosome 3p11.1 (P = 8.0 × 10−7).
Replication
Since rs114209171, located close to F8 gene, association was re-
ported in our GWAS for the ﬁrst time, we sought for replication
in a subset of the INVENT cohort consortium, including 26 112
individuals from 9 cohorts. Results showed that rs114209171T
allele was associated with VTE (OR = 1.08 (1.02–1.14)) at a
P-value of 0.011.
Among the signiﬁcant VTE-associated loci previously re-
ported in genome-wide studies, our study serves as a clear repli-
cation for thewidely known F5, FGA-FGG, F11, F2, PROCR and ABO
loci, and the recently discovered loci in the 19p13.2 and 10q22.1
regions (described as SLC44A2, and TSPAN15 by closest gene
name), although the latter was not genome-wide signiﬁcant in
our study. Non genome-wide signiﬁcant results from other
GWAS suggest the implication of glycoprotein 6 (GP6) (8,9),
STXBP5 (10), VWF (11) and KNG1 (12) in the etiology of VTE. In
agreement with that, our results provided nominally signiﬁcant
replication of these loci (GP6 P = 0.026, STXBP5 P = 0.017, VWF P =
0.0007, KNG1 P = 1.8 × 10−6) (see Supplementary Material,
Table S1).
We failed to replicate previously suggested associations with-
in the CNTN6, SV2C, SUSD1, HIVEP1, F13 V34L, SERPINC1, SERPI-
NA10, FX12 46C/T, C4BPB and OTUD7A loci (testing association
results for our best proxy, deﬁned as the SNP with highest r2,
within 100 kb and with r2 > 0.8).
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Locus on chromosome 19
Since the locus on chromosome 19 (19p13.2) was the only gen-
ome-wide signiﬁcant locus in this study for which there did not
seem to be an obvious candidate gene, i.e. one known to be in-
volved with hemostasis, we used expression proﬁles from the
EUROBATS andGAIT2 cohorts to identify a causal gene underpin-
ning the genetic signal and to investigate a possible biological
mechanism explaining the observed association. First, expres-
sion QTL (eQTL) analyses were performed between the top SNP
in the region (rs9797861) and expression of all genes located in
the 400 Kb ﬂanking region, to identify which genes were affected
by the thrombosis-associated SNP. The highest associations with
expression levels of adjacent genes for this SNP were with
SLC44A2 and ILF3 expression in fat, lymphocytes and whole
blood, and with AP1M2 in whole blood (Table 2). Then, correla-
tions between all the genes in the region and expression levels
of a list of 54 plasma traits related to thrombosis were calculated
in GAIT2 to explore possible pathways that could explain the link
between the locus and thromboembolic disease. We found a sig-
niﬁcant (inverse) genetic correlation (deﬁned as an estimate of
the additive genetic effect shared between a pair of traits) be-
tween QTRT1 expression and S-adenosylmethionine levels, an
intermediary of homocysteine (r = −0.48, P = 1.56 × 10−5), and a
signiﬁcant genetic correlation between TMED1 expression and
Factor XII coagulation activity (r =−0.49, P = 4.13 × 10−5). However,
when we checked the association between rs9797861 and these
two phenotypes in the same individuals from GAIT2, we did
not ﬁnd a signiﬁcant association. We then looked at the associ-
ation between expression of all genes in the region and throm-
bosis outcome in GAIT2 and found no signiﬁcant associations
(Supplementary Material, Table S2).
In an extended search of possible related phenotypes in pub-
licly available GWAS databases, a highly signiﬁcant association
was also found between rs9797861 (using rs6511708 as proxy)
and height in 253 288 individuals from the GIANT consortium
(P = 6.1 × 10−11) (13), and also between rs9797861 (using rs1560711
as proxy) and total cholesterol (TC) and low density lipoprotein
(LDL) levels in the Blood Lipids Consortium (14) (β = 0.049; P = 6.49
× 10−12; n = 88 433). However, a closer look into the region showed
that this was not the strongest association in the region for LDL
Figure 1.Manhattan plot showing association between the SNPs tested and blood clots. The Y-axis represents the –log 10 of the P-value for the association for each SNP.
SNPs are organized by chromosome and position along the X-axis.
Table 1. Association results for the highest associated SNP in each region (cutoff for suggestive association at P < 10−6)
SNP Chrom Position Alleles Frequency P value OR 95%CI Gene context
rs6025 1 169519049 C/T 0.0253 3.6 × 10−137 2.927 [2.715, 3.154] F5
rs529565 9 136149500 C/T 0.6588 7.1 × 10−63 0.723 [0.697, 0.751] ABO
rs4444878 4 187213883 A/C 0.5988 7.0 × 10−28 0.81 [0.780, 0.841] F11
rs1799963 11 46761055 A/G 0.9855 1.3 × 10−24 0.512 [0.456, 0.576] F2
rs7654093 4 155545072 A/T 0.2322 2.0 × 10−19 1.216 [1.166, 1.267] FGG
rs114209171 X 154278797 C/T 0.7756 7.0 × 10−13 1.153 [1.108, 1.200] F8
rs9797861 19 10743126 C/T 0.7601 6.1 × 10−9 1.145 [1.093, 1.199] SLC44A2
rs34234989 20 33774533 D/I 0.7148 6.7 × 10−9 0.885 [0.849, 0.922] PROCR
rs72798544 2 42599605 G/T 0.9735 1.9 × 10−7 0.733 [0.654, 0.820] COX7A2L/KCNG3
rs17490626 10 71218646 C/G 0.8782 2.9 × 10−7 1.165 [1.098, 1.236] TSPAN15
rs113092656 6 11615305 A/G 0.9659 4.4 × 10−7 0.728 [0.646, 0.820] TMEM170B/ADTRP
rs60942712 3 89047759 G/T 0.101 8.0 × 10−7 1.211 [1.124, 1.306] EPHA3
Chorm stands for chromosome number, alleles are expressed as reference allele/effect, OR stands for odds ratio of the effect allele. Frequency refers to the effect allele.
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and TC levels (see regional plot in Supplementary Material,
Fig. S2), and the most strongly associated SNP for LDL and TC
was not the strongest associated SNP with events in 23andMe.
Finally, we investigated the association of rs9797861 with
other related cardiovascular diseases. We tested the association
with CAD in the CARDIoGRAMplusC4D 1000 genomes-based
genome-wide analysis (15) and found that this SNP is also signiﬁ-
cantly associated with CAD, with the T allele conferring in-
creased risk (β = 0.0449; P = 0.00005); moreover, we tested the
association of a proxy for rs9797861 (rs1560711, r2 = 0.90) with is-
chemic stroke and its subphenotypes in the Metastroke consor-
tium and found that the SNP was signiﬁcantly associated with
ischemic stroke (β (T allele) = 0.055; P = 0.00536), especially with
large artery stroke (LAS) (β = 0.1511; P = 0.00048) and to some de-
gree with cardioembolic stroke (CE) (β = 0.0836; P = 0.0361).
Novel suggestive locus on chromosome 6
Since the TMEM170B-ADTRP locus on chromosome 6p24.1 con-
tained a gene that had been previously described to regulate tis-
sue factor pathway inhibitor (TFPI) expression in endothelial cells
(16), we tested the association between our top SNP (rs113092656)
and expression of TFPI in aortic samples from the ASAP study.
The risk allele proved to be signiﬁcantly associated (P = 0.019)
with decreased expression levels of TFPI (Supplementary Mater-
ial, Fig. S3).
Discussion
In contrast to all prior VTE genetic studies that have relied on
clinically diagnosed DVT or PE using compression venous duplex
ultrasonography, computed tomography, Doppler ultrasound,
impedance plethysmography, magnetic resonance, venography,
pulmonary angiography and/or ventilation/perfusion lung scan,
the present study used self-reported data on history of blood
clots obtained through questionnaires fromdeeply genotyped in-
dividuals in the 23andMe cohort. One recent meta-analysis of
GWAstudies of clinically deﬁnedVTE identiﬁed two novel loci as-
sociated with venous thrombosis and conﬁrmed multiple other
known associated loci (6). Interestingly, the Manhattan plots
from the current study and that meta-analysis are almost identi-
cal. As the number of people who obtain their SNP proﬁles
through companies such as 23andMe increases rapidly, the data-
base of genotype and phenotype data that can be obtained using
these datasets for research is becoming one of themost powerful
tools for the discovery of common variants for a wide range of
disease-related phenotypes. Several GWAS have already proven
the reliability and robustness of self-reported phenotypes ob-
tained by 23andMe (17–20). This study contributes to the knowl-
edge of VTE genetics and shows that collection and analysis of
self-reported data is a viable alternative to clinically diagnosed
VTE in GWAS of VTE.
Among the previously reported VTE-associated loci, our study
provides clear replication for thewidely known F5, FGA-FGG, F11,
F2, PROCR and ABO loci, and the recently discovered loci near
SLC44A2, and TSPAN15 from a previous GWAS meta-analysis,
and it strengthens the evidence for other hitherto not genome-
wide signiﬁcant results (GP6, STXBP5, VWF and KNG1). In add-
ition to the previous GWAS ﬁndings, our study reports for the
ﬁrst time a signiﬁcant genome-wide association between
rs114209171, located upstream the F8 structural gene, and throm-
bosis risk. Our results were conﬁrmed in a replication sample of
26 112 VTE cases and controls from the INVENT consortium. High
plasma levels of FVIII are a well-established risk factor for VTE
(21). There have been reports of association between the coding
variant rs1800291 and some coagulation-related phenotypes
(FVIII levels, VTE, stroke) all consisting of candidate-gene studies,
and an open debate whether this is actually the causal variant
is still ongoing. Our lead SNP in this region is in moderate LD
with rs1800291 (r2 = 0.28 in 1000 Genomes phase I Europeans)
and our results show a substantially weaker association for
rs1800291 (P = 9.6 × 10−6), which suggests that rs114209171 repre-
sents a novel genetic risk factor for thrombosis. Finally, we have
also calculated the LD between rs114209171 and rs2096362, re-
cently found in a gene-centric approach study (22) and is r2 = 0.74
(in March 2012 release of 1000 Genomes), which indicates quite
strong LD between these two variants (so, both variants might
be tagging the same locus). However, rs114209171 has a strongest
association with the phenotype in our cohort, which might indi-
cate that rs114209171 could be a better proxy for the causal SNP.
Further studies are needed to elucidate the causal association in
this locus.
Locus on chromosome 19
Among our results, all VTE-associated loci are located in genes
encoding proteins either known to participate in the coagulation
cascade or as inhibitors, except for the recently discovered locus
on chromosome 19. Having new candidate genes outside of the
canonical coagulation system opens the door for discovery of
new pathways for VTE. rs9797861, the highest thrombosis-asso-
ciated SNP in the region, is located in the SLC44A2 coding region
and is in strong linkage disequilibrium (r2 = 0.89) with rs2288904,
which encodes an amino acid change that could be responsible
for the effect. This gene codes for a human leucocyte alloantigen.
However, our results show that expression of other genes in the
region is also affected by rs9797861, which indicates that other
genes in the region should also be taken into consideration.
According to our expression analyses, solute carrier family 44
(choline transporter), member 2 (SLC44A2), Adaptor Protein Com-
plex AP-1 Subunit 2 (AP1M2) and interleukin enhancer binding
factor 3 (ILF3), all showed evidence of being differentially ex-
pressed by the different alleles on rs9797861.
Table 2. eQTL data results in blood, fat and LCL
Source Transcript P-value Beta
EUROBATS (blood) SLC44A2 5.00E−09 0.226784
EUROBATS (blood) ILF3 0.002469 0.118542
GAIT2 (blood) AP1M2 3.28E−015 0.447769
GAIT2 (blood) SLC44A2 2.48E−006 0.270386
GAIT2 (blood) ILF3-AS1 0.008084 0.145566
EUROBATS (fat) SLC44A2 8.42E−10 0.237704
EUROBATS (fat) ILF3 2.24E−07 0.201422
EUROBATS (fat) KRI1 0.000473 0.136727
EUROBATS (LCL) ILF3 7.63E−10 0.238294
EUROBATS (LCL) SLC44A2 1.12E−07 0.206283
EUROBATS (LCL) SMARCA4 2.10E−06 0.184805
EUROBATS (LCL) CARM1 5.05E−05 0.158285
EUROBATS (LCL) ANGPTL6 5.97E−05 0.156777
EUROBATS (LCL) DNMT1 0.000204 0.145163
EUROBATS (LCL) PPAN-P2RY11 0.000341 0.140076
EUROBATS (LCL) PPAN 0.001052 0.128221
EUROBATS (LCL) QTRT1 0.001846 0.121918
EUROBATS (LCL) ZGLP1 0.002041 0.120762
EUROBATS (LCL) DOCK6 0.002135 0.12024
Only results signiﬁcant after correction for 18 genes in 3 tissues are shown. Beta
values refer to the rs9797861T allele.
1870
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/25/9/1867/2384901 by U
niversity of D
undee user on 14 M
ay 2019
Human Molecular Genetics, 2016, Vol. 25, No. 9 |
Further functional analyses will be needed to establish
the identity of the causal gene and the mechanism accounting
for the association in chromosome 19 clearly. This will be a chal-
lenging task, becausewe and others (6) could not ﬁnd any associ-
ation between the most strongly associated SNP in chromosome
19 locus and any intermediate phenotype that is related to coagu-
lation, which limits our ability to identify the mechanistic path-
way by which this locus could be associated with disease.
We did observe strong association between a proxy for our
most strongly associated SNP and LDL and TC levels in the
Blood Lipids Consortium (14), but this was not the strongest asso-
ciation with these lipid phenotypes in the region, and the bio-
logical meaning of these seemingly concordant associations
needs to be further elucidated. Finally, an association between
a proxy for our most strongly associated SNP and height has
also been found in the GIANTConsortium (13), which could be in-
teresting given that body height has been considered a risk factor
for VTE in men (23,24), and that an inverse association was re-
cently found between genetically determined height and CAD
that is partly explained by the association between shorter height
and an adverse lipid proﬁle (25). Further work is clearly needed
to understand the links between these associations, if any, but
exploring this locus further could shed some light on shared
biological pathways.
Common pathways between arterial and venous
thrombosis
It is also interesting to note that rs9797861 (the strongest asso-
ciated SNP in the chromosome 19 region) is also associated
with CAD and stroke. This is an important novel ﬁnding that sug-
gests that still unknown shared pathways exist for venous and ar-
terial thrombosis. Increased risk of CAD among patients
previously diagnosed with VTE as well as increased risk of VTE
in patients with atherosclerosis andmanifest cardiovascular dis-
ease have been reported that suggest commonalities between ar-
terial and venous thrombosis (26). Shared disease mechanisms
for the two diseases have already been established, including
ABO blood group, BMI, activation of blood coagulation, hypoﬁbri-
nolysis and inﬂammation. However, no clear common genetic
factors have been described, beyond the widely known ABO
locus and the recently discovered PROCR gene. This study reveals
a novel locus that could represent the link explaining comorbid-
ities between these two diseases.While themain genetic triggers
of venous thrombosis are abnormalities in coagulation-related
proteins, arterial thrombosis has so far been mainly related to
changes in the vessel wall caused by atherosclerosis, promoting
plaque rupture. A common genetic determinant linking these
diseases opens new views to challenge the understanding of
these diseases which have until now been considered to be dri-
ven by completely different mechanisms.
Other suggestive loci
Four loci were found with suggestive evidence of association
with thrombosis. The locus on chromosome 10q22.1 (near the
TSPAN15 gene) has very recently been implicated in VTE by
Germain et al. (6). TSPAN15 codes for tetraspanin 15. Although a
role in the regulation of hemostasis has been shown for other
members of the tetraspanin family, the association of this gene
with VTE needs to be further investigated. The new SNP on
chromosome 2p21 that exhibits a suggestively associated lies be-
tween the COX7A2L and KCNG3 genes, for which no clear role in
coagulation/hemostasis has been established. The locus on
chromosome 3p11.1 is located upstream of the EPHA3 gene,
which codes for a tyrosine kinase receptor involved in contact-
dependent bidirectional signaling with neighboring cells, and
also lacks a known role in coagulation/hemostasis. The asso-
ciated SNP on chromosome 6p24.1 is located in the TMEM170B-
ADTRP locus. Interestingly, ADTRP codes for the androgen-de-
pendent TFPI-regulating protein. TFPI is amajor natural inhibitor
of coagulation that inhibits the FVII-TFa complex in the presence
of FXa, and it is located mainly on endothelial cells. Reduced le-
vels of TFPI have been associated with ischemic stroke (27), cere-
bral venous thrombosis (28) and DVT (29–31). ADTRP has been
shown to regulate TFPI mRNA expression, cellular distribution
and the cell-associated anticoagulant activity of TFPI in endothe-
lial cells, both in native conditions and in response to androgen
(16), for which it becomes a novel interesting obvious candidate
gene associatedwith VTE risk. Our results indicate that the stron-
gest VTE-associated SNP in the region is also associated with ex-
pression levels of TFPI in the aorta, which supports ADTRP as a
novel thrombotic risk factor that regulates TFPI expression in
the arterial wall.
Strengths and limitations
A concern of the self-reported phenotype approach used in the
present work is the heterogeneity of the phenotype, which in-
cludes venous thrombosis but also cases of stroke. While this
makes interpretability more challenging, our results show that
genetic plots are comparable to clinically diagnosed VTE. Thus,
while novel discoveries in a blood clots self-reported phenotype
are interesting and suggest implication to disease, further repli-
cation on clinically diagnosed speciﬁc diseases would provide
additional validation.
In conclusion, this study extends the current knowledge of
the genetics of VTE by adding for the ﬁrst time information
about associated loci in the sex chromosome, describing a
GWAS association within the F8 locus, providing suggestive evi-
dence of a novel gene (ADTRP) that could be implicated in throm-
bosis by modulating TFPI levels, and describing evidence of a
shared genetic factor on chromosome 19, associated with both
CAD, stroke and VTE. Expression analyses nail down three plaus-
ible causal genes, which may explain the observed comorbidity
for these diseases. Moreover, we show that use of self-reported
data for VTE yields results comparablewith studies based on clin-
ically diagnosed VTE. These latter results open the door to new
larger collaborations between groups with more relaxed pheno-
typing descriptions of VTE, enabling a substantial increase in
power and sample size for the next generation of studies.
Methods
Study sample
The study sample consists of 6135 cases self-reporting history of
blood clots and 252 827 controls of European ancestry belonging
to the 23andMe research participant cohort. All individuals in-
cluded in the analyses provided informed consent and answered
surveys online in accordance with the 23andMe human subjects
protocol, which was reviewed and approved by Ethical & Inde-
pendent Review Services, a private institutional review board
(http://www.eandireview.com). A table with demographics of all
individuals included in the GWAS is provided in Table 3.
Phenotype description
Data for the study were collected within a research framework
wherein research participants, derived from the customer base
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of 23andMe, Inc., a direct-to-consumer genetic information com-
pany, consented to the use of their data for research andprovided
with access to their personal genetic information. Most data on
blood clots came from the questions ‘Have you ever been diag-
nosed with any of the following conditions? (A stroke or a blood
clot)’ (Yes, No, I’m not sure); if Yes: ‘What types of blood clot
or stroke were you diagnosed with? Please check all that apply:
(A blood clot in the brain (an ischemic stroke), A blood clot in
your arms or legs (deep-vein thrombosis or DVT), A blood clot
in your lungs (pulmonary embolism)). Some participants an-
swered only a broadly worded question, either ‘Have you ever
been diagnosed by a doctor with any of the following blood con-
ditions? (Blood clots)’ (Yes, No, I’m not sure); or ‘Have you ever
been diagnosed with a blood clot?’ (Yes, No, I’m not sure).
Cases gave at least one positive response, and controls gave no
positive and at least one negative response. Among 4196 indivi-
duals who reported a speciﬁc diagnosis, 48% reported deep-
vein thrombosis (DVT); 14% reported pulmonary embolism (PE);
18% reported ischemic stroke and the remainder reported mul-
tiple diagnoses, largely DVT and PE (17%).
DNA sampling, genotyping and imputation
DNA extraction and genotyping were performed on saliva sam-
ples by theNational Genetics Institute (NGI), a CLIA-licensed clin-
ical laboratory and a subsidiary of Laboratory Corporation of
America. Samples were genotyped on one of four genotyping
platforms. The V1 and V2 platforms were based on the Illumina
HumanHap550+ BeadChip, including about 25 000 custom SNPs
selected by 23andMe, with a total of about 560 000 SNPs. The V3
platform was based on the Illumina OmniExpress+ BeadChip,
with custom content to improve the overlap with the V2 array,
with a total of about 950 000 SNPs. The V4 platform is a fully cus-
tom array, including a lower redundancy subset of V2 and V3
SNPs with additional coverage of lower-frequency coding vari-
ation, and about 570 000 SNPs. Samples that failed to reach
98.5% call rate were re-analyzed. Individuals whose analyses
failed repeatedly were re-contacted by 23andMe customer ser-
vice to provide additional samples.
We restricted participants to a set of individuals who had
>97% European ancestry, as determined through an analysis of
local ancestry. The reference population data is derived from
public datasets (the Human Genome Diversity Project, HapMap
and 1000 Genomes), as well as 23andMe customers who have re-
ported having four grandparents from the same country. Partici-
pant genotype data were imputed against the March 2012 ‘v3’
release of 1000 Genomes reference haplotypes (32). Further de-
tails about ancestry determinations and imputation are given
in Supplementary Material, Section 1.
Association analyses
Genotyped and imputed SNPs were analyzed according to
logistic regression assuming an additive model for allelic effects,
including covariates for age, gender and the top ﬁve principal
components to account for residual population structure. Results
for the X chromosome are computed similarly, with male geno-
types coded as if they were homozygous diploid for the observed
allele. Selection of the most associated SNP in each region was
done by identifying SNPs with P < 10−5, then grouping these
into intervals separated by gaps of at least 250 kb, and choosing
the SNP with the smallest P within each interval.
Replication for SNP rs114209171was sought in a subsample of
the INVENT consortium consisting on 26 112 VTE cases and con-
trols. Details of the statistical analysis can be found in Germain
et al. (6).
Association with related phenotypes
In order to identify the causal genewithin the associated locus on
chromosome 19, correlations between expression levels of all
genes located within 400 Kb of rs9797861 and 54 phenotypes be-
longing to the coagulation, anticoagulant and ﬁbrinolytic path-
ways were tested in GAIT2 (data not shown). GAIT2 includes 35
extended pedigrees with at least 10 living relatives from 3 or
more generations (a total of 935 individuals) that were identiﬁed
based on a proband with idiopathic thrombophilia (at least one
spontaneous episode of deep venous thrombosis). Expression le-
vels were measured by RNA-seq in whole blood. Paired reads of
49 bpwhere sequenced andmapped to the human genome refer-
ence using BWA (33). We quantiﬁed gene level expression by
counting reads that fall in exons as deﬁned in the GENCODE
v10 annotation. Quantiﬁcations were scaled to the size of the li-
brary to make them comparable across samples and then trans-
formed using a rank-normal transformation. Correlations were
calculated taking into account the family structure using a bivari-
ate variance components model as implemented in SOLAR (34).
Bivariate variance components models allow the partition of
the phenotypic correlation in genetic and environmental compo-
nents (35).We then quantiﬁed the genetic correlation between all
genes locatedwithin 400 Kb of rs9797861 and the thrombosis out-
come in the same sample using the same statistical approach.
Since our analyses showed suggestive correlations between
two of the genes located in the chromosome 19 locus and FXII
coagulant levels as well as levels of an intermediary of homo-
cysteine metabolism (S-adenosylmethionine), we also tested
rs9797861 for association with FXII coagulant levels and homo-
cysteine levels in the GAIT2 sample.
Finally,we tested the association of rs9797861withCAD in the
CARDIoGRAMplusC4D GWAS, a meta-analysis of ≈185 000 CAD
cases and controls (15) andwith 12 389 individuals with ischemic
stroke and 62 004 controls, using data from the Metastroke
consortium (36).
Expression QTL analyses
The strongest associated SNP on chromosome 19 (rs9797861) was
tested for association with the expression levels of all genes lo-
cated within its 400 Kb ﬂanking region (18 genes) in whole
blood, adipose tissue, skin and lymphoblastoid cell lines (LCLs)
using available data from EUROBATS (37) and GAIT2 (38). EURO-
BATS consists of a sample of ∼800 female twins from the Twin-
sUK cohort. For each individual, there are measures of gene
expression obtained from RNAseq in four tissues: adipose tissue,
skin, whole blood and LCLs. Methods to quantify gene expression
and obtain eQTL have been described (37). The association ana-
lysis in the GAIT2 samplewas performedwith SOLAR Eclipse ver-
sion 7.6.6 using RNA-seq data fromwhole blood. Gene expression
Table 3. Demographics from individuals included in the GWAS for
self-reported blood clots
Group N Male Female Age
(0, 30]
Age
(30, 45]
Age
(45, 60]
Age
(60, Inf]
Case 6135 2644 3491 161 759 1643 3572
Control 252 827 134 977 117 850 35 025 72 478 69 615 75 709
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data were normalized using an inverse normal transformation.
We used linear mixed models to allow the decomposition of
the phenotypic variance into genetic, environmental and re-
sidual terms, adjusting by age and sex, and introducing a pedi-
gree bias correction to correct for family structure. The reported
association P-values were determined by likelihood ratio test
(LRT). Further information on GAIT2 and RNA extraction meth-
ods can be found in Folkersen et al. (38) and in Supplementary
Material, Section 2. Association between the strongest associated
SNP on chromosome 6 (rs113092656) and expression of TFPI in
blood vessels was tested in 132 aortic adventitia samples from
the ASAP project (39).
Supplementary Material
Supplementary Material is available at HMG online.
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